Abstract: An expandable and contractible cellular panel 10 comprises a plurality of parallel, aligned, elongated tubular sections 12 secured together at the median region of their adjacent longitudinal margins to form the panel 10. The adjacent tubular sections 12 of the panel 10 are made of a pair of substantially identical separate strips of sheet material from those forming the other adjacent tubular sections 12. The various adjacent pairs of strips are laminated together along their confronting longitudinal margins. Each strip is made of at least two separate flexible substrate sheets 18,20 having completely different appearances, and are secured together by welding together their longitudinal margins.

Abstract: This invention provides for, inter alia, a multipack comprising at least two different bags, wherein the bags are arranged in a predetermined sequence and are joined together in a single block. The inventive multipacks provide for, for example, a simplified method for the transdermal administration of therapeutic agents such as hormones to a patient in need thereof.

Abstract: The invention relates to a hydrophilic cotton pad for skin-care exhibiting a specific surface weight of at least 150 g/m2, and having two different outer sides of which the fibers are entangled. In the invention, the first outer side has hollow striae apart by a spacing s1 between 1 and 8 mm and having a depth d of at least 0.25 mm and wherein at least 50% of the fibers are entangled. The pad of the invention is used to apply skin-care products, such as cosmetics, to the skin.

Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound; and (iii) seeding the first solution or the second solvent or the pre-suspension.

Abstract: The invention concerns a pharmaceutical composition with gastric residence and controlled release, characterized in that it comprises two or three layers and contains (a) an active principle associated with a excipient modifying its release; (b) a system generating carbon dioxide in a swelling polymer hydrophilic matrix; (a) and (b) capable of being included in a common layer or in separate layers.

Abstract: An improved antimicrobial composition is described as a liquid concentrate. The liquid concentrate includes a complex resulting from an in-situ reaction of a cation source, an oxidant, a halide source having at least one iodine atom, and a non-mineral acid, or a mixture of a non-mineral acid to about 50% of a hydrophilic solvent by volume.

Abstract: A mat of mineral fibers has a random or quasi-random fiber orientation. The fibers have diameters which, for the great majority of them, are 2.5 to 4.5 micrometers, and a length of 2 to 15 cm. Its density is less than 40 kg/m3. Its resistance to compression, for a crushing of 10%, is equal to at least 0.5 kN/m2. The fineness of the fibers and their random distribution imparts to the mat an exceptional lightness and an excellent flexibility, making possible the perfect application of the mat on cylindrical surfaces.

Abstract: The present invention relates to a gelatin soft capsule having the properties of removal of oral smell and cleaning of oral cavity, which contains the ingredient for masking an oral smell as an active ingredient. More particularly it relates a gelatin soft capsule comprising core ingredients and shell ingredients, wherein said core ingredients comprise i) 40˜90 wt % of at least one base material selected from safflower seed oil, olive oil and medium chain triglycerides, ii) 1˜40 wt % of natural or artificial flavor for refreshing oral cavity, iii) 0.1˜10 wt % of at least one artificial sweetener selected from saccharine, aspartam and stevioside; and said shell ingredients comprise the gelatin as a base material, glycerin, D-sorbitol, citric acid, surfactant and edible pigment.

Abstract: Th present invention relates to nutritional and pharmaceutical compositions. More particularly it is concerned with improving compositions which due to the presence of an efflorescent component may be unstable and prone to decomposition and/or spoilage. The problem is overcome by incorporating one or mote anhydrous compounds into the composition in an amount capable of sequestering any water which may be released from one or more water containing components. The preferred anhydrous compounds are anhydrous or calcined MgSO4 and CaO.

Abstract: An implantable or insertable medical device is provided which comprises (a) a superoxide dismutase mimic and (b) a polymeric release region. Upon administration to a patient, the polymeric release region controls the release of the superoxide dismutase mimic, which is beneficially selected from a metal-chelate superoxide dismutase mimic and a nitroxide superoxide dismutase mimic. Also provided is a method of making an implantable or insertable medical device.

Abstract: The present invention concerns a suspension of crystallized particles of an EPI-hNE protein, methods for preparing said suspension, a dry powder aerosol derived from said suspension, an inhalable pharmaceutical formulation comprising said suspension or said dry powder aerosol, and the use of said inhalable pharmaceutical formulation in the treatment of various pathological conditions.

Abstract: The present invention concerns a food composition comprising a foodstuff and substantially pure eritadenine. The invention also concerns a food additive comprising a liquid or solid-material intended to be added to a foodstuff, said material being supplemented with substantially pure eritadenine. Furthermore, the invention concerns methods for preparation of the food composition so as to provide a food composition having an increased level of eritadenine in comparison to the inherent eritadenine level of the foodstuff(s) included in the food composition.

Abstract: The invention discloses an extract of the leaves of Cajanus Cajan(L.) Millsp. and a process for the preparation of them. The invention also discloses the new uses of the leaves of Cajanus Cajan(L.)Millsp. and extract thereof, i.e. the uses for the preparation of medicaments for the treatment of ischemic necrosis of caput femoris and osteoporosis, for the improvement of hemorheological index, for anti-inflammatory and analgecization, for the enhancement of immunological function, and for the treatment of angina of coronary heart disease, fracture, cerebral infarction, bedsore, infected surface of wound and infected surface of wound of open fracture.

Abstract: Iron oxide-silicon dioxide-titanium dioxide mixed oxide is produced by burning vaporizable compounds of iron, silicon and titanium together in a hydrogen/oxygen flame. The mixed oxides may be used as UV absorbers in cosmetics.

Abstract: A fibrous material, which can be an absorbent material, includes a plurality of natural fibers treated with a carboxylic acid-based odor control agent, which are able to withstand insults with an aqueous liquid without dissolving the odor control agent. The acid-based odor control agent is bound to the natural fibers by an organosilicone polymer binder. The binder is water-insoluble, and can form a highly gas permeable coating. The binder is also highly porous, so as to expose the odor control agent to ammonia and other odoriferous gases which it is intended to control.

Abstract: The present invention is directed to an improved sustained release drug delivery device comprising a drug core, a unitary cup, and a permeable plug.

Abstract: A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.

Abstract: The present invention relates to an oral preparation of esculetin with controlled release. The oral preparation of esculetin with controlled release of the present invention comprises a gel-forming polymer base, preferably hydroxypropylmethylcellulose. The preparation may be coated with an enteric polymer base such as hydroxypropylmethylcellulose acetate succinate to thereby enhance solubility in the intestines. When orally administered, the preparation can continuously release esculetin. Thus, the administration frequency and dose can be reduced and a therapeutic effect on arthropathy can be established.

Abstract: The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N/cm, density of 1-10 mg/cm3, chamber diameter of more than 0.75 mm and less than 4 mm and/or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin. The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibres. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and/or thrombin.

Abstract: An expanding tablet is described comprising a drug release controlling membrane material. After swallowing, the tablet hydrates and expands such that the membrane ruptures to directly expose some surfaces of the core tablet to hydrating and eroding liquids, thus generating in situ a tablet which is platform supported on non-exposed surfaces, and which releases active ingredient in approximately zero order fashion. More particularly, the dosage form is adapted for controlled release of various pharmaceuticals. A working embodiment of the tablet was a spray-coated tablet comprising a core having greater than 25% of an expandable material which expands upon exposure to an aqueous environment and at least one active ingredient, e.g., glipizide, and an outer rupturable coating surrounding the core comprising a rate release modifying membrane and a water-soluble modifier. A method for administering an active ingredient also is described.